Dechert Advises Royalty Pharma on its US$255 Million Acquisition of Agios Pharmaceuticals, Inc.’s Royalty Interest in IDHIFA® (enasidenib)
June 12, 2020
Dechert is advising Royalty Pharma on IP-related matters in its acquisition from Agios Pharmaceuticals, Inc., of sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib), as well as its rights to outstanding regulatory milestone payments. IDHIFA® is an oral, targeted therapy approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.
Royalty Pharma is the industry leader in acquiring pharmaceutical royalties. Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism.
The Dechert team advising Royalty Pharma includes intellectual property partner Carl A. Morales, Ph.D., associate Blaine M. Hackman, Ph.D. and patent agent Michael G. Manas, Ph.D.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
